ScoreComparison
Why is Immunome, Inc. ?
1
Negative results in Sep 25
- OPERATING CASH FLOW(Y) Lowest at USD -185.03 MM
- NET SALES(HY) At USD 4.01 MM has Grown at -23.87%
- RAW MATERIAL COST(Y) Grown by 101.26% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 139.35%, its profits have risen by 34.6%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Immunome, Inc. for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Immunome, Inc.
139.35%
0.32
76.22%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
60.59%
EBIT Growth (5y)
-276.15%
EBIT to Interest (avg)
-150.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.27
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.73
EV to EBIT
-9.82
EV to EBITDA
-9.95
EV to Capital Employed
-232.88
EV to Sales
209.81
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-74.03%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET PROFIT(HY)
Higher at USD -100.85 MM
CASH AND EQV(HY)
Highest at USD 540.67 MM
-14What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -185.03 MM
NET SALES(HY)
At USD 4.01 MM has Grown at -23.87%
RAW MATERIAL COST(Y)
Grown by 101.26% (YoY
OPERATING PROFIT(Q)
Lowest at USD -59.41 MM
PRE-TAX PROFIT(Q)
Lowest at USD -57.46 MM
NET PROFIT(Q)
Lowest at USD -57.46 MM
Here's what is working for Immunome, Inc.
Cash and Eqv
Highest at USD 540.67 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Immunome, Inc.
Net Sales
At USD 4.01 MM has Grown at -23.87%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Operating Cash Flow
Lowest at USD -185.03 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Operating Profit
Lowest at USD -59.41 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Pre-Tax Profit
Lowest at USD -57.46 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -57.46 MM has Fallen at -28.89%
over average net sales of the previous four periods of USD -44.58 MMMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -57.46 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Net Profit
At USD -57.46 MM has Fallen at -28.89%
over average net sales of the previous four periods of USD -44.58 MMMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Raw Material Cost
Grown by 101.26% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
